In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.
Research output: Contribution to journal › Journal article › Research › peer-review
Standard
In vitro antileukemic effect of a new anthracycline analogue, MEN 11079. / Biscardi, Monica; Caporale, Roberto; Pagliai, Gabriella; Leoni, Franco; Bernabei, Pietrantonio; Santini, Valeria; Ciolli, Stefania.
In: Leukemia research : a Forum for Studies on Leukemia and Normal Hemopoiesis, Vol. 27, No. 12, 2003, p. 1125-34.Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - In vitro antileukemic effect of a new anthracycline analogue, MEN 11079.
AU - Biscardi, Monica
AU - Caporale, Roberto
AU - Pagliai, Gabriella
AU - Leoni, Franco
AU - Bernabei, Pietrantonio
AU - Santini, Valeria
AU - Ciolli, Stefania
N1 - Keywords: Acute Disease; Adult; Aged; Annexin A5; Anthracyclines; Antineoplastic Agents; Apoptosis; Cell Cycle; Daunorubicin; Female; Humans; Idarubicin; K562 Cells; Leukemia, Myeloid; Leukocytes, Mononuclear; Male; Middle Aged; P-Glycoprotein; Propidium; Reverse Transcriptase Polymerase Chain Reaction
PY - 2003
Y1 - 2003
N2 - The biological activity of MEN 11079, a new daunorubucin analogue with a fluorine atom in C(8) of ring A, was investigated in the human leukemic cell lines K-562 and in mononuclear cells (MNCs) of 40 patients with acute myeloid leukemia (AML) and the activity compared to two well-characterized anthracyclines, idarubicin (IDA) and doxorubicin (DOXO). IDA and MEN 11079 were more active than DOXO in cytotoxicity tests (WST-1 assay). IDA and MEN 11079 ID(50) values were also significantly different from each other (K-562: P=0.038; MNCs: P=0.003). Moreover, the range was 0.002-4.300 microM for IDA and 0.002-0.670 microM for MEN 11079, in the MNCs. Therefore, the latter appeared to assure a smaller variability of response in the AML cells. Apoptosis assays (performed using Annexin-V assay and propidium iodide) and cell cycle studies demonstrated that the MEN 11079 effective concentration was 10-fold lower than the DOXO and IDA ones. MDR (Pgp and MRP1 proteins), as measured by semiquantitative RT-PCR, cytofluorimetric and functional analysis of proteins, was similarly elicited by IDA and MEN 11079. In conclusion, the response of the cells to the new anthracycline indicates that there is greater cytotoxic activity of this molecule than IDA and DOXO. Its narrower ID(50) range may allow for a more predictable response in the clinical setting.
AB - The biological activity of MEN 11079, a new daunorubucin analogue with a fluorine atom in C(8) of ring A, was investigated in the human leukemic cell lines K-562 and in mononuclear cells (MNCs) of 40 patients with acute myeloid leukemia (AML) and the activity compared to two well-characterized anthracyclines, idarubicin (IDA) and doxorubicin (DOXO). IDA and MEN 11079 were more active than DOXO in cytotoxicity tests (WST-1 assay). IDA and MEN 11079 ID(50) values were also significantly different from each other (K-562: P=0.038; MNCs: P=0.003). Moreover, the range was 0.002-4.300 microM for IDA and 0.002-0.670 microM for MEN 11079, in the MNCs. Therefore, the latter appeared to assure a smaller variability of response in the AML cells. Apoptosis assays (performed using Annexin-V assay and propidium iodide) and cell cycle studies demonstrated that the MEN 11079 effective concentration was 10-fold lower than the DOXO and IDA ones. MDR (Pgp and MRP1 proteins), as measured by semiquantitative RT-PCR, cytofluorimetric and functional analysis of proteins, was similarly elicited by IDA and MEN 11079. In conclusion, the response of the cells to the new anthracycline indicates that there is greater cytotoxic activity of this molecule than IDA and DOXO. Its narrower ID(50) range may allow for a more predictable response in the clinical setting.
M3 - Journal article
C2 - 12921951
VL - 27
SP - 1125
EP - 1134
JO - Leukemia Research
JF - Leukemia Research
SN - 0145-2126
IS - 12
ER -
ID: 8463419